UNSPSC 51183508: Metformin embonate

This classification denotes an anti-diabetic agent with the molecular formula C23H16O6.2C4H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9AZJ7GJZ1, chemically known as 2-naphthalenecarboxylic acid, 4,4'-methylenebis(3-hydroxy-, compd. with n,n-dimethylimidodicarbonimidic diamide (1:2), but more generally known as metformin embonate, which bears US NIH Compound Identifier 62987.

European Medicines Agency schedules metformin embonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08831MIG. Most nations, for tariff purposes, schedule metformin embonate under HS 29252900. SMILES: CN(C)C(=N)NC(=N)N.CN(C)C(=N)NC(=N)N.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51183508 Metformin embonate is a Commodity code identifying a specific pharmaceutical active ingredient sold through state and local cooperative purchasing vehicles and direct government procurement. State and local governments acquire metformin embonate and other generic multi-source pharmaceuticals primarily through statewide cooperative purchasing agreements that consolidate demand across multiple jurisdictions and establish master contracts with manufacturers and authorized wholesalers. The issuing bodies are state departments of administration and cooperative purchasing alliances that serve state agencies, local government facilities, schools, and other public entities. Vendors must comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with authorized pharmaceutical wholesalers, provide detailed product data including National Drug Codes and unit-of-measure specifications, carry comprehensive insurance including commercial general liability of at least $5,000,000 per occurrence, and accept administrative fees typically assessed at 3 percent on all contract purchases.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products spanning metformin embonate and other specified medications, with proposals due March 26, 2026. The RFP covers participating state and local government facilities across Minnesota and Oregon and requires vendors to supply products through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Award decisions will be based on fixed pricing (10 percent weight), administrative compliance (5 percent), EDI capability (5 percent), 3 percent administrative fee acceptance (5 percent), and price competitiveness (75 percent). The contract term is two years for new responders with optional extensions, while incumbent amendments extend through June 30, 2028. MMCAP reserves the right to make sole, dual, or multiple awards based on therapeutic considerations and member-specific needs, with awarded vendors effective July 1, 2026.